Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2007 Oct 15:7:40.
doi: 10.1186/1471-230X-7-40.

Meta-analyses of FibroTest diagnostic value in chronic liver disease

Thierry Poynard  1 , Rachel Morra, Philippe Halfon, Laurent Castera, Vlad Ratziu, Françoise Imbert-Bismut, Sylvie Naveau, Dominique Thabut, Didier Lebrec, Fabien Zoulim, Marc Bourliere, Patrice Cacoub, Djamila Messous, Mona Munteanu, Victor de Ledinghen
Affiliations
Meta-Analysis

Meta-analyses of FibroTest diagnostic value in chronic liver disease

Thierry Poynard et al. BMC Gastroenterol. .

Abstract

Background: FibroTest (FT) is a biomarker of liver fibrosis initially validated in patients with chronic hepatitis C (CHC). The aim was to test two hypotheses, one, that the FT diagnostic value was similar in the three other frequent fibrotic diseases: chronic hepatitis B (CHB), alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD); and the other, that the FT diagnostic value was similar for intermediate and extreme fibrosis stages.

Methods: The main end points were the FT area under the ROC curves (AUROCs) for the diagnosis of bridging fibrosis (F2F3F4 vs. F0F1), standardized for the spectrum of fibrosis stages, and the comparison of FT AUROCs between adjacent stages. Two meta-analyses were performed: one combining all the published studies (random model), and one of an integrated data base combining individual data. Sensitivity analysis integrated the independency of authors, lenght of biopsy, prospective design, respect of procedures, comorbidities, and duration between biopsy and serum sampling.

Results: A total of 30 studies were included which pooled 6,378 subjects with both FT and biopsy (3,501 HCV, 1,457 HBV, 267 NAFLD, 429 ALD, and 724 mixed). Individual data were analyzed in 3,282 patients. The mean standardized AUROC was 0.84 (95% CI, 0.83-0.86), without differences between causes of liver disease: HCV 0.85 (0.82-0.87), HBV 0.80 (0.77-0.84), NAFLD 0.84 (0.76-0.92), ALD 0.86 (0.80-0.92), mixed 0.85 (0.80-0.93). The AUROC for the diagnosis of the intermediate adjacent stages F2 vs. F1 (0.66; 0.63-0.68, n = 2,055) did not differ from that of the extreme stages F3 vs. F4 (0.69; 0.65-0.72, n = 817) or F1 vs. F0 (0.62; 0.59-0.65, n = 1788).

Conclusion: FibroTest is an effective alternative to biopsy in patients with chronic hepatitis C and B, ALD and NAFLD. The FT diagnostic value is similar for the diagnosis of intermediate and extreme fibrosis stages.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow sheet of the included databases.
Figure 2
Figure 2
Meta-analysis of the observed area under the ROC curves (AUROC) assessed in published studies of Fibrotest diagnostic value. AUROCs were all significantly higher for Fibrotest than the random 0.50 value (upper panel) (P < 0.001). There was no significant difference between the different liver diseases.
Figure 3
Figure 3
Meta-analysis of the standardized area under the ROC curves (AUROC) assessed in published studies of Fibrotest diagnostic value. There was no significant difference between the different liver diseases.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, Thabut D, Ratziu V, Mercadier A, Benhamou Y, Hainque B. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV-Fibrosure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol. 2004;3:8. doi: 10.1186/1476-5926-3-8. - DOI - PMC - PubMed
    1. Poynard T, Imbert-Bismut F, Munteanu M, Ratziu V. FibroTest-FibroSURE:towards a universal biomarker of liver fibrosis? Expert Rev Mol Diag. 2005;5:15–21. doi: 10.1586/14737159.5.1.15. - DOI - PubMed
    1. Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, Imbert-Bismut F, Messous D, Charlotte F, Di Martino V, Benhamou Y, Poynard T. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol. 2003;39:222–230. doi: 10.1016/S0168-8278(03)00171-5. - DOI - PubMed
    1. Poynard T, Zoulim F, Ratziu V, Degos F, Imbert-Bismut F, Deny P, Landais P, El Hasnaoui A, Slama A, Blin P, Thibault V, Parvaz P, Munteanu M, Trepo C. Longitudinal assessment of histology surrogate markers (Fibrotest-Actitest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gast. 2005;100:1970–1980. doi: 10.1111/j.1572-0241.2005.41957.x. - DOI - PubMed
    1. Naveau S, Raynard B, Ratziu V, Abella A, Imbert-Bismut F, Messous D, Beuzen F, Capron F, Thabut D, Munteanu M, Chaput JC, Poynard T. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol. 2005;3:167–174. doi: 10.1016/S1542-3565(04)00625-1. - DOI - PubMed

Publication types